SUMO Biosciences Inc. develops next generation small molecule immuno oncology drugs to address unmet medical needs in aggressive lymphoma and in colorectal cancers. The SUMO E1 enzyme is a novel immuno oncology target. We have discovered an allosteric mechanism to inhibit the SUMO E1 enzyme, and use this approach to develop small molecule drugs that are orally available and straight forward to synthesize. The team has extensive expertise in SUMO modification biology and in small molecule drug discovery. We have filed multiple patents.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
small molecule immuno oncology drug
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):